Prediction of conversion to wet age-related macular degeneration (AMD)

Not Applicable

Conditions: Age-related macular degeneration
Eye Diseases

Registration Number: ISRCTN13798759

Lead Sponsor: Moorfields Eye Hospital NHS Foundation Trust

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Ongoing

Sex: All

Target Recruitment: 800

Inclusion Criteria

Consecutive patients at each site who meet the following inclusion and exclusion criteria:
1. Adults who are >=50 years and <=100 years
2. Fellow eyes of patients with unilateral treatment naïve neovascular AMD at baseline
3. Media clarity, pupillary dilation and patient cooperation for adequate imaging
4. Ability to give informed consent

Inclusion criteria for retrospective part only in addition to above:
1. Fellow eyes of patients with unilateral neovascular AMD initiated on treatment in the past 12-15 months
2. Had OCT and OCTA for study eye at baseline

Exclusion Criteria

1. Treatment initiation for unilateral neovascular AMD more than 15 months prior to recruitment.
2. Late wet AMD in the study eye
3. Co-existent ocular disease: Any other ocular condition that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study
4. Any patient who has opted out of their information being used for research nationally or locally at any site
5. Patients participating in a clinical trial with an ophthalmic experimental therapy will be excluded
6. Study eye (neCNV) is not treated with anti-VEGF within 6 months for non-wAMD reason

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Age, gender, ethnicity, smoking history, and date of anti-Vascular Endothelial Growth Factor injection of non-study eye measured using patient records at baseline<br>2. Visual acuity of study eye using ETDRS logs measured at baseline, month 12 and 24 <br>3. Scans of the study eye using Optical Coherence Tomography measured at baseline, month 12 and 24 <br>4. neCNV eyes converted to wAMD measured using Blue Auto Fluorescence and Optical Coherence Tomography Angiography measured at baseline, month 12 and 24

Secondary Outcome Measures